Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
We offer IHC Antibody Products against multiple biomarker targets with sufficient validation, reliable quality, flexible authorization and service support!
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 16.8 kDa. The protein migrates as 20-26 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to different glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD69, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Decitabine/Cedazuridine | ASTX-727-LD; ASTX-727-10; E-7727/decitabine; Decitabine/E7727; ASTX-727 | Approved | Astex Pharmaceuticals Inc, National Cancer Institute | INAQOVI, Inaqovi, Inqovi | United States | Myelodysplastic Syndromes | Otsuka Pharmaceutical Co Ltd | 2020-07-07 | Leukemia, Myelogenous, Chronic; Leukemia; Solid tumours; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Triple Negative Breast Neoplasms; Neoplasms; Mesothelioma; Pancytopenia; Leukemia, Myeloid, Acute; Glioma; Cytopenia; Metastatic breast cancer; Nervous System Neoplasms | Details |
Mecobalamin | E-0302 | Approved | Methycobal, Naso B12, Myelogen, 悦敏兴, 弥尔神, 弥可保, 曲力, 奇信, ROZEALAMIN, NASOCOBAL, RHINOCOBAL | Peripheral Nervous System Diseases; Autistic Disorder; Neuritis; Neuralgia; Vitamin B 12 Deficiency; Amyotrophic Lateral Sclerosis; Fibromyalgia | Details | |||||
Azacitidine | NSC-102816; 5-aza-CR; CC-486; NS-17; U-18496; NEX-18; NEX-18a | Approved | Celgene Corp | 维达莎, Vidaza, Onureg | United States | Myelodysplastic Syndromes | Bristol-Myers Squibb Company | 2004-05-19 | Leukemia, Myelomonocytic, Juvenile; Contracture; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Breast Neoplasms; Prostatic Neoplasms; Tuberculosis, Pulmonary; Brain Neoplasms; Sarcoma; Osteosarcoma; Hepatic Insufficiency; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Multiple Myeloma; Thyroid Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Lung Neoplasms; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Non-Small-Cell Lung; Leukemia, Large Granular Lymphocytic; Melanoma; Myelodysplastic-Myeloproliferative Diseases; Cerebral Palsy; Nasopharyngeal Neoplasms; Intestinal Neoplasms; Ependymoma; Leukemia, Myeloid; Lymphoma, T-Cell, Peripheral; Head and Neck Neoplasms; Solid tumours; Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Plasmacytoma; Neoplasms; Lymphoma, Large B-Cell, Diffuse; beta-Thalassemia; Hodgkin Disease; Glioblast | Details |
Triclabendazole | EGA-230B; CGA-89317; NVP-EGA230 | Approved | Novartis Pharma Ag | Egaten, Fasinex, Triclathera | Iran | Fascioliasis | Novartis Pharma Ag | 1989-01-01 | Fascioliasis | Details |
Decitabine | 5-aza-CdR; NSC-127716; AzadC; E-7373; DAC | Approved | Eisai Co Ltd | Dacogen, 达珂 | Mainland China | Myelodysplastic Syndromes | Mgi Pharma Inc | 2006-05-02 | Burkitt Lymphoma; Multiple Myeloma; Cycloplegia; Lymphoma, Mantle-Cell; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Neuroblastoma; Vulvar Neoplasms; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Colorectal Neoplasms; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Thyroid Neoplasms; Adenocarcinoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Lung Neoplasms; Anemia, Sickle Cell; Myelodysplastic-Myeloproliferative Diseases; Precancerous Conditions; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms, Male; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Metastasis; Melanoma; Thyroid Cancer, Papillary; Esophageal Neoplasms; Hematologic Neoplasms; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid, Accelerated Phase; Leukemia; Lymphoma, B-Cell, Marginal Zone; Solid tumours; Purpura, Thrombocytopenic, Idiopathic; Liver Neoplasms; Erectile Dysfunction; Hypotension; Anaphylaxis; Thalassemia; Leukemia, Myelogenous, Chronic; Neutropenia; Myelodysplastic Syndromes; L | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Curcumin | VOLT-03; VOLT-3; NSC-32982 | Phase 3 Clinical | University Of Pennsylvania | Neuralgia; Lung Neoplasms; Lymphoma, T-Cell, Cutaneous; Adenocarcinoma, Mucinous; Cigarette Smoking; Cervical Intraepithelial Neoplasia; Cognitive Dysfunction; Uterine Cervical Dysplasia; Asthma; Osteoarthritis; Primary Myelofibrosis; Colorectal Neoplasms; Dentist-Patient Relations; Periapical Diseases; Prostatic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tobacco Use Disorder; Oral Submucous Fibrosis; Thrombocythemia, Essential; Cognition Disorders; Uterine Cervical Neoplasms; Stomatitis; Neoplasm Metastasis; Macular Degeneration; Condylomata Acuminata; Carcinoma, Non-Small-Cell Lung; Aortic Aneurysm, Abdominal; Pancytopenia; Adenocarcinoma; Crohn Disease; Diabetes Mellitus; Hypogonadism; Renal Insufficiency, Chronic; Periodontitis; Lichen Planus, Oral; Diabetes Mellitus, Type 2; Neoplasms; Stomach Neoplasms; Spasm; Digestive System Diseases; Pain; Radiodermatitis; Gastritis, Atrophic; Depression; Myelodysplastic Syndromes; Metabolic Dysfunction-Associated Steatotic Liver Disease; Polycythemia | Details |
Azacitidine/Cedazuridine | ASTX-030 | Phase 3 Clinical | Otsuka Pharmaceutical Co Ltd | Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Guadecitabine Sodium | SGI-110; S-110; 0RB89YH367 (UNII code) | Phase 3 Clinical | Otsuka Holdings Co Ltd | Klatskin Tumor; Carcinoma, Hepatocellular; Adenocarcinoma; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Melanoma; Gallbladder Neoplasms; Lung Neoplasms; Leukemia, Myeloid, Acute; Fallopian Tube Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Peritoneal Neoplasms; Cholangiocarcinoma; Ovarian Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pancreatic Neoplasms; Myeloproliferative Disorders; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Stomach Neoplasms; Pheochromocytoma; Carcinoma, Renal Cell; Chondrosarcoma; Kidney Neoplasms | Details |
EF-009 | EF-009 | Phase 2 Clinical | Everfront Biotech Co Ltd | Pancreatic Neoplasms | Details |
NTX-301 | NTX-303 | Phase 2 Clinical | Southern Research Institute, Pinotbio Inc | Solid tumours; Ovarian Neoplasms; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Neoplasms; Carcinoma, Transitional Cell; Leukemia, Myeloid, Acute; Glioma | Details |
FdCyd | NSC-48006; Ro-5-1090 | Phase 2 Clinical | City Of Hope National Medical Center, National Cancer Institute | Head and Neck Neoplasms; Esophageal Neoplasms; Neoplasms; Mesothelioma; Urinary Bladder Neoplasms; Breast Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
Azacitidine (Boryung Pharmaceutical) | Phase 2 Clinical | Boryung Pharmaceutical Co Ltd | Neoplasms | Details | |
Decitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk) | EPI-01; EPI01; NN 7533 | Phase 2 Clinical | Epicdestiny | Anemia, Sickle Cell | Details |
GSK4172239D | GSK-4172239-D | Phase 1 Clinical | Glaxosmithkline Plc | Hematologic Diseases; Anemia, Sickle Cell | Details |
This web search service is supported by Google Inc.